RECEIVED CENTRAL FAX CENTER

Page 1 of 2

INFORMATION DISCLOSURE	Atty. Docket No.: 275.00100101	Serial No.: 10/780,797		
	Applicant(s): MUNN et al.	Confirmation No.: 1508		
STATEMENT	Application Filing Date: 02/17/04	Group: 1614		
	Information Disclosure Statement mailed:	Anril 14 , 2008		

04/14/2008 11:57 FAX 6123051228

## ILS. PATENT DOCUMENTS

Examiner Initial	Capy Enclosed	Document Number	Date	Name	Class	Subelass	Filing Date If Appropriate
		NONE					

## FOREIGN PATENT DOCUMENTS

Examiner	Сору	Document Number	Date	Country	Class	Subclass	Trans	lation
Initial	Englosed						Yes	No
		NONE						
							-	_
					l			i l

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy	Document Description
	х	"Chemotherapy Before Breast Surgery is Valuable." CANCERWISE, The University of Texas MD Anderson Cancer Center, Featured Article. Retrieved from the Internet on February 25, 2008. Retrieved from http://www.cancerwise.org/july_2005/display.cfm?id=8FD089A2-41F1-4B7C-84 4D5550459E1368&method=displayFull&color=green . 4 pages.
	х	"New Treatments" Seattle Cancer Care Alliance, Breast Cancer Program. Retrieved from the Internet on February 25, 2008. Retrieved from http://www.seattlecca.org/patientsandfamilies/adultCare/clinicalProgs/breastCanc er/newTreatments/NeoadjuvantChemotherapy.htm. 1 page.
	х	Chemotherapy Information/Chemotherapy Terms. Retrieved from the Internet on February 25, 2008. Retrieved from http://www.chemocare.com/whatis/important_chemotherapy_terms.asp. 2 pages.
	х	Hou et al., "The immunosuppressive effects of 10 mg/kg cyclophosphamide in Wistar rats," 2007. Environ. Toxicology and Pharmacology, 24:30-36.

EXAMINER	Date Considered		
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

PAGE 24/28 \* RCVD AT 4/14/2008 12:40:38 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-5/2 \* DNIS:2738300 \* CSID:6123051228 \* DURATION (mm-ss):21-14

Q102

APR 1 4 2008 OMB No. 0651-0011 Page 2 of 2

INFORMATION	Atty. Docket No.: 275.00100101	Serial No.: 10/780,797	
DISCLOSURE	Applicant(s): MUNN et al.	Confirmation No.: 1508	
STATEMENT	Application Filing Date: 02/17/04	Group: 1614	
	Information Disclosure Statement mailed:	April /4 , 2008	

Examiner Initial	Copy Enclosed	Occument Description
	X	On-Line Article. 2008. MedicineNet.com. Information on Generic Name: Cyclophosphamide, Brand Name: Cytoxan. Retrieved from the Internet on April 9, 2008. Retrieved from http://www.medicinenet.com/script/main/art.asp?articlekey=12343&pf=3&page=1. 2 pages.
	· X	Moyo et al., "High-dose cyclophosphamde for refractory autoimmune hemolytic anemia," 2002, Blood. 100(2):704-706.
	X.	Nygaard et al., "Blood and spleen lymphocytes as targets for immunotoxic effects in the rat - a comparison," 2002. Toxicology, 174:153-161.
	X	Ochalek, "Divergence between delayed-type hypersensitivity (DTH) to polyoma tumor-associated antigen and antitumor efficacy in polyoma-bearing recipients of therapeutic non-cytolytic, DTH-mediating lymphocyctes," 1993. <i>Immunol. Lett.</i> 38(2):97-102.
	Х	On-Line Article. "Taxotere®/Cytoxam® Superior to Standard Adriamycin®/Cytoxan as Adjuvant Therapy in Breast," Cancer Consultants.com. Retrieved from the internet on February 29, 2008. Retrieved from <a href="http://professional.cancerconsultants.com/print.aspx?id=35701">http://professional.cancerconsultants.com/print.aspx?id=35701</a> 2 pages.
	X	Reiner et al., "Pulse Cyclophosphamide Therapy for Refractory Autoimmune Thrombocytopenic Purpura," 1995. <i>Blood</i> , 85(2):351-358.

EXAMINER /James Anderson/	Date Considered 07/15/2008		
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

PAGE 25/28 \* RCVD AT 4/14/2008 12:40:38 PM [Eastern Daylight Time] \* SVR:USPTO EFXRF-5/2 \* DNIS:2738300 \* CSID:6123051228 \* DURATION (mm-ss):21-14